TickerFacts.

Compare

BridgeBio Pharma, Inc. vs Nature's Sunshine Products Inc vs HUTCHMED (China) Ltd vs Organogenesis Holdings Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearBridgeBio Pharma, Inc.
BBIO		Nature's Sunshine Products Inc
NATR		HUTCHMED (China) Ltd
HCM		Organogenesis Holdings Inc.
ORGO
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$502.08M$480.14M$548.51M$564.17M
Revenue growth (YoY)+126.3%+5.7%-13.0%+17.0%
Gross marginn/a72.4%38.7% (computed)n/a
Operating margin-104.2%5.2%-7.1%7.9%
Net margin-146.0%4.3%83.3%6.6%
Net income-$732.94M$20.45M$456.91M$37.03M
EPS (Diluted)-$3.78$1.06$0.52$0.15
Operating cash flow-$445.91M$35.32M-$64.66M-$10.31M
Free cash flow-$447.01M$28.84M-$78.81M-$24.46M
Cash & equivalents$570.12M$93.89M$71.33M$93.68M
Total assets$936.02M$261.15M$1.75B$598.73M
Total liabilities$3.01B$99.59M$501.83M$164.81M
Shareholders' equity-$2.09B$161.55M$1.25B$300.13M
Return on year-end equityn/a12.7%36.5%12.3%
Shares outstanding194.77M17.51Mn/a126.95M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearBridgeBio Pharma, Inc.Nature's Sunshine Products IncHUTCHMED (China) LtdOrganogenesis Holdings Inc.
Latest$502.08M
Ended 2025-12-31		$480.14M
Ended 2025-12-31		$548.51M
Ended 2025-12-31		$564.17M
Ended 2025-12-31
1 year earlier$221.90M
Ended 2024-12-31		$454.36M
Ended 2024-12-31		$630.20M
Ended 2024-12-31		$482.04M
Ended 2024-12-31
2 years earlier$9.30M
Ended 2023-12-31		$445.32M
Ended 2023-12-31		$838.00M
Ended 2023-12-31		$433.14M
Ended 2023-12-31
3 years earlier$77.65M
Ended 2022-12-31		$421.91M
Ended 2022-12-31		$426.41M
Ended 2022-12-31		$450.89M
Ended 2022-12-31
4 years earlier$69.72M
Ended 2021-12-31		$444.08M
Ended 2021-12-31		$356.13M
Ended 2021-12-31		$467.36M
Ended 2021-12-31